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ABSTRACT 
AIm: The molecular mechanism of epileptogenesis in temporal lobe epilepsy is still unclear. Experimental studies have suggested that matrix 
metalloproteinases have important roles in this process, but human studies are limited. The aim of this study was to assess the expression of 
MMP-9, MMP-2 and their tissue inhibitors (TIMP-1 and TIMP-2) in patients with temporal lobe epilepsy with hippocampal sclerosis (TLE-HS). 
mAterIAl and methOds: The tissue samples from temporal neocortex and hippocampus were obtained from patients with temporal 
lobe epilepsy with hippocampal sclerosis who had undergone anterior temporal lobectomy for recurrent medically resistant seizures. 
Immunohistochemical methods were used to determine the expression of MMP-9, MMP-2 and their tissue inhibitors. Tissue samples were also 
analyzed with transmission electron microscopy.    
results: The immunoreactivity for MMP-9 both in hippocampal and temporal neocortical neurons was stronger than that of MMP-2. 
Additionally, there was a mild reaction for its tissue inhibitor TIMP-1 as with TIMP-2. The TEM analysis of the hippocampus revealed that there 
was apparent ultra-structural damage on the pericarya and neuropil of some neurons. There was obvious damage in the mitochondria and 
the nuclear membrane.  
COnClusIOn: The preliminary results of this study revealed that MMP-9 may have a role in patients with drug resistant TLE-HS.     
KeywOrds: Hippocampal sclerosis, Matrix metalloproteinase-9, Temporal lobe epilepsy 
ÖZ 
AmAÇ: Temporal lob epilepsisinde moleküler epileptogenez mekanizmalar halen tam anlaşılamamıştır. Deneysel çalışmalar matriks 
metaloproteinazların bu süreçte önemli rolü olduğunu ileri sürmektedir, ancak bu konuda insan çalışmaları kısıtlıdır. Çalışmanın amacı, 
hipokampal sklerozun eşlik ettiği temporal lob epilepsisi (TLE-HS) olan hastalarda MMP-9, MMP-2, TIMP-1 ve TIMP-2 ekspresyonunu 
değerlendirmektir. 
yÖntem ve GereÇler: İlaca dirençli epilepsi nedeniyle anterior temporal lobektomi yapılan TLE-HS hastalarından alınan hipokampus ve 
temporal neokorteks dokuları kullanıldı. MMP-9, MMP-2, TIMP-1 ve TIMP-2 ekspresyonunu incelemek için immünohistokimyasal yöntemler 
kullanıldı ve dokular transmisyon elektron mikroskopisiyle incelendi.     
BulGulAr: MMP-9 immünoreaktivitesi hem hipokampal hem de neokortikal nöronlarda MMP-2’ye göre daha güçlü bulundu. Doku inhibitörüü 
olan TIMP-1’in de ılımlı bir immünoreaktivite gösterdiği tespit edildi. TEM analizinde hipokampal nöronlarda özellikle mitokondriyal ve nükleer 
membranın belirgin derecede hasara uğradığı tespit edildi.  
sOnuÇ: Çalışma, MMP-9’un TLE-HS’da rol oynayabileceğini düşündürmektedir.       
AnAhtAr sÖZCÜKler: Hipokampal skleroz, Matriks metalloproteinaz-9, Temporal lob epilepsi
INTRODUCTION
Temporal lobe epilepsies (TLEs) comprise a heterogeneous 
group of disorders sharing the same topographical seizure 
onset. TLE with hippocampal sclerosis is the most common 
type of epilepsy in adults. In one third of the patients seizures 
cannot be controlled by pharmacological therapies and may 
require further surgical approaches. Therefore, it is necessary 
to understand the molecular mechanisms of this devastating 
disease. 
Neuronal degeneration is one of the hallmarks of mesial 
TLE (MTLE). A preferential neuron loss is characteristic in the 
CA1, CA3 and the hilus regions of the hippocampus. Besides, 
extra-hippocampal neuron loss has also been observed in 
MTLE in the entorhinal cortex, pyriform cortex and amygdala. 
However, it is not clear whether neuronal loss is the cause 
or the consequence of repetitive seizures (4, 11). Another 
important finding in MTLE with hippocampal sclerosis (MTLE-
HS) is chronic astroglial activation which results in sclerosis 
by increasing inflammatory cytokine production and thus 
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potentiating excessive synaptic activity and inducing a 
“travelling effect” as activated astrocytes migrate to the 
epileptic focus (2, 13, 27). During epileptogenesis, aberrant 
synaptic plasticity and mossy fiber sprouting have been 
assumed as the main reason of epileptic focus formation. 
Mossy fiber sprouting is characterized by dentate granule 
cell axons forming synapses with cells in the granular layer 
and inner molecular layer rather than in the CA3 region of 
the hippocampus (33). Although the environmental changes 
deriving from seizures that drive sprouting are yet unclear, 
gliosis, release of cytokines, growth factors and adhesion 
molecules from activated astrocytes and microglia may have 
crucial role (42). According to Pitkanen and Sutula, sprouting 
is progressive and is brought on by recurrent seizures (29). 
The recurrent excitation hypothesis is supported by the fact 
that mossy fibers are glutamatergic axons and by evidence of 
excitatory circuit formation within the inner molecular layer 
(33). On the contrary, it is believed that mossy fiber sprouting 
serves to reform inhibitory circuits that are lost during the 
initial damage to neurons where mossy fibers synapse 
primarily on inhibitory inter-neurons (11). Besides, it has been 
noted that mossy fiber sprouting occurs secondary to neuron 
loss (15). 
Recently, matrix metalloproteinases’ (MMPs) are found to be 
a possible key factor in epilepsy. MMPs are a large family of 
zinc dependent proteinases that are considered major ele-
ments conducting the extracellular matrix (ECM) remodeling 
and have pivotal role in cancer invasion and metastasis (1, 34). 
Many studies have identified that MMPs are associated with 
various central nervous system (CNS) pathologies including 
stroke, traumatic brain injury, cerebral arteriovenous malfor-
mation, influenza associated encephalopathy and in bacte-
rial meningitis where it has been identified as a risk factor for 
developing neurological sequel (8, 22, 39). Moreover, many 
studies have reported that MMP-9 has implication in synaptic 
plasticity, learning and memory (21, 25, 28, 36). Also, MMP-
2 has been implicated in dendritic remodeling (36), axonal 
sprouting (30), synaptic plasticity, and learning in the hippo-
campus (5, 21). 
The activity of MMPs is counterbalanced by their natural 
inhibitors, the tissue inhibitors of matrix metalloproteinase’s 
(TIMPs). In recent studies a physiological role of MMP-9 and 
its tissue inhibitor, TIMP-1, has been postulated in neuronal 
plasticity as well as long term potentiation (16, 24). Recently, 
Wilczysky and colleagues have reported MMP-9 is an essential 
molecule in pentylenetetrazole epileptogenesis and MMP-
9 deficiency diminished aberrant synaptogenesis (41). In 
relation to epilepsy it is suggested that MMP-9 cleaves 
ECM molecules in and around the synaptic cleft where this 
is thought to be a necessary step in the cascade of events 
leading to new synapse formation. 
The studies mentioned above are all experimental and the 
role of MMPs in human epilepsy is still obscure. Therefore, 
the aim of this study was to determine the hippocampal 
and neocortical expressions of MMP-9 and MMP-2 and their 
natural tissue inhibitors TIMP-1 and TIMP-2 in human MTLE-
HS by using immunohistochemical methods. Here, we report 
the preliminary results of this study.
MATERIAL and METHODS
Patient Selection
Patients with mesial temporal lobe epilepsy associated with 
hippocampal sclerosis were enrolled in this study. Tissue 
samples of hippocampus and temporal neocortex were 
obtained from 3 (1 female, 2 male) patients with temporal 
lobe epilepsy with hippocampal sclerosis who had anterior 
temporal lobectomy surgery for recurrent medically resistant 
epileptic seizures. Informed consent for the use of tissue in 
research was obtained before surgery. 
All of the patients’ presurgical evaluations were consisted of 
detailed history and neurological examination, interictal and 
ictal electroencephalogram (EEG), neuropsychological testing 
and neuroimaging studies. All of the patients were refractory 
to multiple trials of antiepileptic drugs. Neuroimaging studies 
also revealed that none of them had a progressive disease 
in CNS. After surgical removal of the anterior temporal lobe, 
hippocampus and amygdala, conventional neuropathologic 
examination revealed mesial temporal sclerosis. 
Tissue Processing 
Adequate amount of the resected materials were immediately 
fixed in 10 % buffered in formalin for 24 h. Formalin-fixed 
tissue samples were embedded in paraffin and cut into 5 μm 
sections. 5µm thick serial sections were collected on poly-L-
lysine coated slides (Sigma–Aldrich, St. Louis, MO, USA) and 
incubated overnight at 56oC. 
Adequate amount of tissue samples were fixed with 
phosphate buffered (pH 7.4) 2.5% glutaraldehyde solution for 
trensmision electron microscopy. 
Immunohistochemistry
For MMP-9, MMP-2, TIMP-1 and TIMP-2 immunohistochemis-
try, paraffin sections were deparaffinized and blocked for en-
dogenous peroxidase activity with methanol containing 3% 
H2O2 for 15  min. and for nonspecific binding with universal 
blocking reagent (BioGenex, San Ramon, CA, USA) for 10 min. 
at room temperature (37). Anti-rabbit MMP-9 (Neomarkers 
cat#RB-1539P), MMP-2 (Neomarkers cat#RB-1588P), TIMP-
1 (Neomarkers cat# RB-1531P), TIMP-2 (Neomarkers cat# 
RB-1489P) and anti-rabbit cleaved caspase-3 (Asp 175) (Cell 
Signaling #9661) antibody diluted in dilution buffer (1/5000, 
1/400, 1/200, 1/400, 1/250, respectively) were applied for 
overnight at +4 0C in a humidified chamber. For negative 
controls the primary antibodies were replaced by normal rab-
bit IgG serum (Vector Lab. Burlingame, CA, USA) at the same 
concentration. After several washes in PBS, sections were 
incubated with biotinylated goat anti-rabbit IgG secondary 
antibody (1/400 dilution Vector Lab. Burlingame, CA, USA) for 
1h. followed by LSAB streptavidin-peroxidase complex (Dako, 
Carpinteria, CA, USA) incubation for 45 min. and were rinsed 
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with PBS. Antibody complexes were visualized by incubation 
with diaminobenzidine (DAB) chromogen (BioGenex). Sec-
tions were counterstained with Mayer’s hematoxylin (Dako), 
dehydrated, mounted and examined by a Zeiss-Axioplan 
(Oberkochen, Germany) microscope.
Transmission Electron Microscopy (TEM) Analysis
Tissue samples were fixed with phosphate buffered (pH 7.4) 
2.5% glutaraldehyde solution followed by 1 hour at 4°C with 
2% osmium tetroxide. Samples were dehydrated through 
a gradually increasing series of ethanol and embedded in 
Araldite resin (Araldite CY 212, 91 ml + dodecenyl succinic 
anhydride (DDSA) 84 ml + N,N-dimethylbenzylamine (BDMA) 
3.5 ml, TAAB Company, England). Semi-thin (1 μm) and 
thin (40–60 nm.) sections were cut using diamond knives 
on a Leica ultramicrotome (Leica ultracut, UCT, Leica MZ6, 
England). Ultra-thin sections were collected on copper grids. 
In thin sections, double-contrast staining was applied with 
uranyl acetate (100 ml methanol and 5 g uranyl acetate) 
and Reynold’s lead nitrate solution (1.76 g sodium citrate, 
1.33 g lead nitrate, 50 ml distilled water and 8 ml 1N.NaOH). 
Thin sections were examined using a LEO 906 transmission 
electron microscope (Leo 906E, Zeiss, Germany).
RESULTS
MMP-9
Despite the cytoarchitectural damage, the neuronal 
expression of MMP-9 was more significant than MMP-2, 
particularly on mossy fibers. Both neurons and glial cells were 
labeled by the MMP-9 in CA1 and CA2 hippocampal subfields. 
Likewise, strong immunoreactivity for MMP-9 was seen in the 
granular cell layer of the dentate gyrus (Figure 1A, MMP-9). 
In the temporal neocortex the cytoplasmic immunoreactivity 
for MMP-9 was so strong enabling to visualise the dendritic 
and axonal projections (Figures 1E, F).
MMP-2
The neurons in the CA1 (Figure 1B, MMP-2) and CA2 (Figure 1C, 
MMP-2) regions showed strong cytoplasmic immunoreactivity 
for MMP-2, however there was mild immunoreaction in CA3 
neurons due to the damaged cytoarchitecture (Figure 1D, 
MMP-2). In the neocortex, pyramidal neurons showed strong 
cytoplasmic immunoreactivity, but the glial cells were not 
immunostained (Figures 1E, F, MMP-2).
Figure 1: Representative photomicrograph of MMP9/2 and their natural tissue inhibitors TIMP-1/2 stainings in hippocampal subregions 
and neocortex in human MTLE-HS patients. Localisation of the antibodies were revelaled in hippocampal and cortical fileds by line.
MMP9 and -2 were found to be expressed in all hippocampal subfields. MMP9 and -2, on the other hand, were expressed at higher 
levels in DG, CA1 and CA2 subregion in comparison with the CA3 hippocampal subfield. A pronounced expression of TIMP-1/2 was 
notable in all CA1 subregions. The neocortical TIMP-1 expression was very similar to TIMP-2 expression. Negative-control section. 
Please note the absence of MMP9/2 and TIMP-1/2 immunostainings in hippocampal subregions and neocortex. Scale bars represent 
50 μm. 
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TEM Analysis
The TEM analysis of the hippocampus revealed that there 
was apparent ultra-structural damage on the pericarya 
and neuropil of some neurons. (Figures 3A, B). There was 
an obvious damage in the mitochondria and the nuclear 
membrane was ondulated and fragmented in hippocampal 
neurons. Especially in some hippocampal neurons pericarya 
was invaded by dense structure in cytoplasm (Figure 3B). 
By TEM, some of the sub-cellular components and synaptic 
connections of the neocortex showed a normal structural 
organization. But, some of the pyramidal neurons were 
clearly observed with euchromatic nucleus, including very 
active nucleoli and subcellular organelles (Figures 3C,D). 
The necrotic pericarya were observed with an irregular 
shape and dense cytoplasm containing many vacuoles, and 
a definitive pycnotic nucleus with nucleoli. There was an 
obvious mitochondrial damage such as cristae degeneration 
and matrix loss in the cytoplasm of both hippocampal and 
neocortical neurons (Figures 3A-D). Moreover, in some areas 
there was a considerable number of normal appearing myelin 
sheaths with axoplasm (Figure 3D). Moreover, TEM analysis 
compatible with the caspase-3 immunostaining and also 
reflected the immune results. 
DISCUSSION
Recent studies have linked MMPs to various CNS disorders 
including multiple sclerosis, Alzheimer’s disease, malignant 
glioma, Parkinson’s disease (24). Also in epilepsy it is 
demonstrated that kindling progression persistently 
increased MMP-9 protein expression and activity in the mouse 
hippocampus, whereas acute convulsions had little effect on 
TIMP-1
The CA1 neurons exhibited a weak immunoreactivity with 
TIMP-1 (Figures 1A,B TIMP-1). Moreover, the reaction was also 
weak in the mossy fibers in CA1 and CA2 subregions (Figures 
1 B, C; TIMP-1) while no immunoreaction was detected in the 
CA3 subregion of human hippocampus (Figure 1D; TIMP-1). 
However, the immunoreactivity was weak in the pyramidal 
neurons in the granular cell layer of the dentate gyrus (Figure 
1A; TIMP-1). The neocortical reactivity for TIMP-1 in neurons 
was strong in parallel with MMP-9 (Figures 1E, F; TIMP-1).
TIMP-2
There was a moderate cytoplasmic TIMP-2 immunolabelling 
localized in the CA1 hippocampal subregion neurons (Figure 
1B; TIMP-2), and a strong mossy fibers immunolabelling were 
also observed in CA2 and CA3 hippocampal subregions 
(Figures 1 C, D; TIMP-2). The neocortical TIMP-2 expressions 
were very similar to TIMP-1 expression (Figures 1E, F; TIMP-2).
Negative control immunostaining with normal rabbit IgG 
confirmed the specificity of MMP9/2 and TIMP-1/2 staining 
patterns in hippocampal subregions and neocortex (Figures 
1 A- F; Negative control panel). 
Caspase-3
The antibody specific for activated caspase-3 selectively 
labeled the cytoplasm of cells that had a morphology 
consistent with apoptosis. Occasional nuclear staining was 
observed in neocortex. In CA subregions of the hippocampus, 
activated caspase-3-labelled cells were clearly detected 
(Figures 2 A-C). 
Figure 2: Localization of Caspase-3 protein in human hippocampal subregions and neocortex in MTLE patients. Caspase-3 
immunoreactvity was clearly observed in CA1 (A), CA2 (B) and CA3 (C) subregions. There was weakly immunolabelled with Caspase-3 
in dentate gyrus (D). Scale bars represent 50 μm.
A B C D
E F
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and persistent influx of Ca+2 through NMDA receptors are 
considered as major causes of epileptogenesis (7). It has 
been reported that the expression and activity of MMP-9 
depend on NMDA receptor activation and are associated 
with LTP development (21, 25). Moreover, activation of 
NMDA receptors leads to MMP mediated modification of cell 
adhesion molecules and the development of dendritic spines 
(38). Dendritic spine morphology and synaptic potentiation 
are dynamically modulated by ECM proteins and cell surface 
proteins with which they interact. It is suggested that ECM 
remodelling has an important role in synaptic plasticity. 
MMP-9 (23). In parallel with this, previous studies revealed 
that MMP-9 mRNA levels increased in response to neuronal 
depolarization in the rat hippocampus (32). Konopacki et 
al. also demonstrated that MMP-9 mRNA is transported to 
dendrites and synapses in the hippocampal dentate gyrus 
after seizure in kainic acid treated rats (19).
There are convincing preclinical studies demonstrating that 
the expression and activity of MMP-9 is regulated by repetitive 
activation of NMDA receptors (23). In fact, the inhibition of 
NMDA receptors prevented PTZ-induced convulsions and 
kindling (9). Besides, excessive levels of synaptic glutamate 
Figure 3: The ultrastructure of hippocampus (A, B) and neocortex (C, D) with some cellular components are seen in MTLE patients. 
Nucleus with definitive nucleoli and with ondulated membrane of a pericaryon was shown structural damage (A). Generally, pericaryon 
and neuropil (Np) with subcellular elements were not seen in normal appearance (A-D). These pericaryons have an euchromatic nuclei 
(N) with definitive nucleoli (No). Some pericaryon of hippocampal tissue were observed different structural condition; such as more 
accumulation of dense granules and organells in cytoplasm (double arrows). The pericaryons of cortical tissues were in normal condition 
with definitive nuclei and nucleoli (No). Neurophilic areas showed some destructional arrangement. But, the myelin sheaths with many 
regular lamellae and axoplasm were clearly observed in normal condition (D; with arrows). The cytoplasm of the pericaryon with many 
organells and amount of inclusions and heterochromatic nucleus (N) were seen (A-D) in hippocampus and neocortex. Marked inner 
membrane forming cristae break down and matrix loss in some mitochondria (A, D). N: Nucleus, No: Nucleolus, A: Axoplasma, Np: 
Neuropilic area, M: Mitochondria. Scale bars: A, D: 2 μm; B, C: 5 μm.
A B
C D
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tissue based human epilepsy studies reflect the late stage of 
the epileptogenetic processes. This study is the first study in 
the medical literature demonstrating that MMP-9 expression 
in the hippocampus is increased in human MTLE-HS just as 
in the case of experimental epilepsy models. The preliminary 
results of our study showed that the neuronal expression of 
MMP-9 was significant, particularly on mossy fibers and the 
granular cell layer of the dentate gyrus as well as temporal 
neocortex. In experimental models it has been noted that 
once activated MMP-9 can be inhibited by TIMP-1. Together 
MMPs and TIMPs control the pericellular environment, 
including the turnover of ECM proteins, bioavailability of 
growth factors and cytokines and shedding of membrane 
receptors (34). Moreover, TIMP-1 has an increased expression 
pattern following chemical SE and amygdala stimulation 
induced SE (3, 20, 26). However, different from experimental 
studies, we found that TIMP-1 expression was weak in the 
hippocampus of the human MTLE-HS. The tissue material 
belongs to patients with medically refractory epilepsy that 
suggests that in the late stage of epilepsy TIMP- 1 expression 
is diminished. According to these findings it can hypothesize 
that increased MMP-9 expression can be a result of a 
disinhibition process. Still, it is important to bear in mind that 
epileptogenesis in experimental models can be different than 
human epileptogenesis.
This study also showed severe neuronal loss both in the CA 
subregions of the hippocampus and temporal neocortex. 
This apoptotic cell loss was very severe in the CA subregions. 
Moreover, the electron microscopic analysis of the 
hippocampus revealed severe mitochondrial and nuclear 
damage. Mitochondrial dysfunction and oxidative stress 
are known to be the acute consequences of injuries inciting 
acquired epilepsies. Besides, there are evidences supporting 
the role of mitochondrial oxidative stress not merely as a 
consequence of seizures, but an active contributor to seizures 
and epileptogenesis (40).
To our knowledge, our study is the first study showing that 
MMP-9 is associated with drug resistant MTLE -HS. However 
there are some limitations of our study. First of all, our data 
reflects only a small number of patients. Besides, the lack of 
comparisons with normal controls and other neurological 
diseases impeded us to make more clear suggestions. For 
all that because of the complexity to design tissue material 
based studies in human TLE, we think that our preliminary 
results will provide additional data in understanding the 
mechanism of epileptogenesis. Moreover, our results provide 
additional data about the mitochondrial dysfunction in 
human temporal lobe epilepsy. We hope that further studies 
will help understanding the mechanisms involved in seizure-
induced cellular damage which is an essential basis for the 
development of rational neuroprotective strategies. 
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Wilczynsky et al. demonstrated that the sensitivity of PTZ 
epileptogenesis is decreased in MMP-9 knockout mice but 
is increased in a transgenic rat line overexpressing MMP-9 
(41). In addition to this, electron microscopic studies revealed 
that MMP-9 is associated with hippocampal dendritic spines 
bearing excitatory synapses, where both the MMP-9 protein 
levels and enzymatic activity strongly increased upon seizures. 
Furthermore in the same study, seizure evoked pruning of 
dendritic spines and aberrant synaptogenesis were decreased 
in MMP-9 deficiency. It has also been suggested that cleaving 
the ECM molecules in and around the synaptic cleft by MMP-
9 activity may be an essential step in the cascade of events 
leading to new synapse formation (41). 
In parallel to these findings Mizoguchi et al. provided 
additional data suggesting that mossy fiber sprouting 
induced by repeated PTZ treatment was reduced in MMP-
9 null mice compared to wild type mice, suggesting that 
increased hippocampal MMP-9 activity is associated with 
sprouting of mossy fibers (23). Besides, the previous studies 
have also revealed that several MMPs are acutely upregulated 
after status epilepticus (12). These findings suggest that MMP-
9 takes part in epileptogenesis both in acute and chronic 
processes. 
The studies assessing the changes in MMP/TIMP ratio and 
MMP activity have shed some light on the developmental and 
pathological processes that occur in CNS (18, 31, 43). In vivo 
experiments showed that TIMP-1 has implication in neuronal 
death and axonal sprouting in pathological situations as 
well as in the synaptic mechanisms underlying learning and 
memory in physiological conditions. In epilepsy, the up-
regulation of MMP inhibitors is also demonstrated in several 
studies. For instance, a broad spectrum MMP inhibitor can 
prevent kainate-induced neurodegeneration (6, 17). The up-
regulation of the TIMPs may act as a compensatory mechanism 
to counterbalance the increased expression of MMPs. These 
data support the idea that the control of proteolysis is 
instrumental for pathological and physiological processes 
in the brain (17). Overall these experimental evidences 
emphasize the role of MMP-9, as a key participant in neural 
death, aberrant synaptic plasticity and neuroinflammation 
that directly effects remodeling of synaptic linkage and 
that could represent a pharmacological target in epilepsy. 
Although there is cumulative evidence indicating MMP-9 
is a key factor in epileptogenesis in experimental models, 
its role in human epilepsy is still obscure. In a clinical study 
in children with prolonged febrile seizures and convulsive 
status epilepticus, it is reported that serum MMP-9 levels and 
the ratio of MMP-9 to TIMP-1 is elevated when compared to 
patients with simple partial seizures, West syndrome and 
controls (35). In a Norwegian cohort designed to identify 
possible variants of the MMP-9 gene associated with TLE failed 
to show any polymorphisms in selected single nucleotide 
polymorphism of the human MMP-9 gene that are associated 
with TLE, MTLE-HS or TLE with febrile seizures (14).
In human epilepsy it is impossible to know what happens 
during the early stages of epileptogenesis and the findings of 
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